← All trials
NCT06210646
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 29, 2022
- Primary completion
- Jun 29, 2024
- Completion date
- Jun 29, 2024
- First posted
- Jan 18, 2024
- Last posted
- Sep 19, 2024
- Enrollment
- 800
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kafrelsheikh UniversityLead sponsor
- Kafrelsheikh UniversityOfficial
- Kafrelsheikh UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.